Journal

Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease

Read time: 1 mins

Published:30th Nov 2020

Author: Sellmayr M, Hernandez Petzsche MR, Ma Q, Krüger N, Liapis H, Brink A et al.

Source: Journal of the American Society of Nephrology

Availability: Pay for access, or by subscription

Ref.:J Am Soc Nephrol. 2020 Dec;31(12):2773-2792

DOI:10.1681/ASN.2020040523

Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease

Background: The roles of asymptomatic hyperuricemia or uric acid (UA) crystals in CKD progression are unknown. Hypotheses to explain links between UA deposition and progression of CKD include that (1) asymptomatic hyperuricemia does not promote CKD progression unless UA crystallizes in the kidney; (2) UA crystal granulomas may form due to pre-existing CKD; and (3) proinflammatory granuloma-related M1-like macrophages may drive UA crystal-induced CKD progression.

Methods: MALDI-FTICR mass spectrometry, immunohistochemistry, 3D confocal microscopy, and flow cytometry were used to characterize a novel mouse model of hyperuricemia and chronic UA crystal nephropathy with granulomatous nephritis. Interventional studies probed the role of crystal-induced inflammation and macrophages in the pathology of progressive CKD.

Results: Asymptomatic hyperuricemia alone did not cause CKD or drive the progression of aristolochic acid I-induced CKD. Only hyperuricemia with UA crystalluria due to urinary acidification caused tubular obstruction, inflammation, and interstitial fibrosis. UA crystal granulomas surrounded by proinflammatory M1-like macrophages developed late in this process of chronic UA crystal nephropathy and contributed to the progression of pre-existing CKD. Suppressing M1-like macrophages with adenosine attenuated granulomatous nephritis and the progressive decline in GFR. In contrast, inhibiting the JAK/STAT inflammatory pathway with tofacitinib was not renoprotective.

Conclusions: Asymptomatic hyperuricemia does not affect CKD progression unless UA crystallizes in the kidney. UA crystal granulomas develop late in chronic UA crystal nephropathy and contribute to CKD progression because UA crystals trigger M1-like macrophage-related interstitial inflammation and fibrosis. Targeting proinflammatory macrophages, but not JAK/STAT signaling, can attenuate granulomatous interstitial nephritis.

Read abstract on library site Access full article

Hyperkalaemia

Containing relevant Learning Zones, guidelines, trials and news.

A digital image of two human kidneys, stylised in blue and red

Chronic Kidney Disease

Containing relevant Learning Zones, guidelines, trials and news.

Digital close up of human kidney glomerulus and the Bowman Capsule

Glomerulonephritis

Containing relevant Learning Zones, guidelines, trials and news.

Featured Learning Zones

patient receiving dialysis, hospital image

Learning Zone

Chronic Kidney Disease Learning Zone

Chronic Kidney Disease (CKD) is a disease that can often lead to a need for haemodialysis and kidney transplantation. New CKD treatments are emerging which focus on delaying CKD disease progression and the need for transplantation.

You may be interested in...

Guideline

Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) for the diagnosis of Cushing's syndrome: Genetics of Cushing's syndrome

Recent advancements in high-throughput sequencing have significantly enhanced our understanding of the genetics behind Cushing’s syndrome. Experts from the French Society of Endocrinology and French Society of Endocrinology and Pediatric Endocrinology reviewed genetic predispositions, resulting in a consensus statement on screening for Cushing disease and adrenal Cushing’s syndrome. Discover their key findings and recommendations.

Guideline

Consensus on diagnosis and management of Cushing's disease: a guideline update

The Pituitary Society’s Consensus Workshop brought together over 50 experts to refine the clinical approach to Cushing’s disease. This comprehensive review and collaborative discussion resulted in updated recommendations for diagnosis, treatment, and management, highlighting key areas for future research. Discover the latest consensus on optimizing patient outcomes in Cushing’s disease.

Guideline

Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024

Background and purpose: Two novel enzyme replacement therapies (ERTs), studied in phase 3 trials in late-onset Pompe patients, reached marketing authorization by the European Medicines Agency in 2022 and 2023. The European Pompe Consortium (EPOC) updates and extends the scope of the 2017 recommendations for starting, switching and stopping ERT.